Ashutosh Agarwal, PhD

Ashu Agarwal is an Associate Professor of Biomedical Engineering and Associate Director of the Dr. John T Macdonald Foundation Biomedical Nanotechnology Institute at the University of Miami. His undergraduate degree from Indian Institute of Technology, and his PhD from University of Florida are both in Materials Science and Engineering. He then gathered postdoctoral research experience in Biomedical Engineering at Columbia University, and at the Wyss Institute for Biologically Inspired Engineering at Harvard University. The mission of his Physiomimetic Microsystems Laboratory at the University of Miami is to develop human relevant organ mimic platforms for discovery of therapies and drugs, for modeling of disease states, for conducting mechanistic studies, and for differentiation, maturation and evaluation of stem cells. The lab is supported by multiple NIH consortium grants, Early stage commercialization grants from Wallace H. Coulter Foundation, and a Sponsored research project from Mallinckrodt Pharmaceuticals.

Joana Almaça, PhD


Dr. Almaça is an assistant professor of medicine at the University of Miami Miller School of Medicine. She trained as an electrophysiologist in Portugal and Germany. Dr. Almaça’s current research focuses on the vasculature of the islet. In her work, Dr. Almaça is testing the hypothesis that microvascular dysfunction in the islet leads to a disturbance of hormone secretion, to glucose intolerance, and eventually to diabetes.

Mark Atkinson, PhD

Professor, Director of the UFDI, American Diabetes Association, Eminent Scholar Chair UF Department of Pathology, Immunology and Laboratory Medicine. nPOD Executive Director

Professor Atkinson’s research is broad in scope but directed at identifying a prevention and/or cure for Type 1 (i.e., insulin-dependent, juvenile) diabetes. The key to achieving this goal is an improved understanding of the interactions between environmental, immunologic, and genetic factors that underlie the inability to form immunological tolerance to the insulin secreting pancreatic beta cells. To achieve this goal, our laboratory seeks to directly define methods (e.g., immunointervention with self-antigens, gene therapy) for disease prevention in non-diabetic subjects identified to be at increased risk for the disease or diabetic subjects through pancreatic transplantation in association with novel forms of immunotherapy.

Mehdi Benkahla, PhD

I graduated from the Faculty of Sciences of Tunis, Tunisia in 2012 with a Master of Science degree in Microbiology. Then, I was awarded an Erasmus Mundus Ph.D. scholarship and joined Pr. Didier Hober research group at the University of Lille in France where I studied enterovirus infections and their implications in type 1 diabetes.

Thereafter, I began working as a postdoctoral fellow in the group of Prof. Matthias von Herrath at the La Jolla Institute for Immunology in July of 2018. I’m currently studying HLA class I expression as well as the viral pathogenesis of type 1 diabetes using pancreatic tissue samples obtained from nPOD.

Richard Benninger, PhD

 

Dr. Benninger joined the Barbara Davis Center faculty in 2011. The main goals of Dr. Benninger’s research include understanding novel signaling pathways in the islet of Langerhans that enhance the regulation of hormone secretion; how disruptions to these signaling pathways cause islet dysfunction in diabetes; and how we can manipulate these signaling pathways to improve islet function towards developing new treatments for individuals with diabetes. He is utilizing state-of-the-art quantitative fluorescence microscopy, including two-photon microscopy, fluorescence lifetime imaging, polarization imaging and FRET in studying pancreatic islet dysfunction in diabetes. Dr. Benninger has developed an integrative model of how different cell-cell communication mechanisms dynamically interact within the islet. They have gained understanding into how this impact in-vivo islet function and glucose homeostasis and are now demonstrating that gap junction channels can be modulated to improve islet function and insulin secretion in models of diabetes. Overall his work applies sophisticated quantitative techniques and predictive quantitative models to link emergent multi-cellular properties of the islet of Langerhans to in-vivo physiology and diabetes, and test novel hypotheses regarding these properties that may be clinically important.

Giovanni Bossi, PhD

Giovanna Bossi is Principal Scientist at Immunocore. She has over 15 years’ experience in research and development, gained at Immunocore Ltd, UK. Giovanna leads Cell Biology research and preclinical activities aiming to develop TCR-based therapeutics for treatment of autoimmune diseases such as T1 diabetes. Giovanna joined the Autoimmune group in 2017 after spending previous 9 years in Oncology where she contributed to understand mechanism of action of the first in human ImmTAC (tabentafusp) for treatment of cutaneous melanoma and uveal melanoma. Tebentafusp demonstrated prolonged overall survival (OS) compared to investigator’s choice therapy in metastatic uveal melanoma patients in a Phase III trial. Tebentafusp is the first T cell receptor (TCR) therapeutic to demonstrate a survival benefit.

Following the completion of her DPhil from the Cellular Immunology Unit at the University of Pavia (Italy), a serial of Post Doctoral Research associated positions at Cancer Instititute IFOM-IEO in Milan and at the Sir William Dunn School of Pathology at University of Oxford, she joined Immunocore Ltd in 2006. Her area expertise span from cancer biology to cytotoxic T cells, cancer immunotherapy and autoimmune immunotherapy on which she has presented at International meetings and has contributed to various publications.

Marcus Buggert, MSc, PhD

Marcus conducted his PhD at Karolinska Institutet, Sweden. After post-doctoral studies at University of Pennsylvania, he came back to Karolinska Institutet where he joined Center for Infection Medicine as an Assistant Professor and Principal Investigator. His research is focused on human circulating and resident memory T cells in health and disease through the access to human organ donors and other unique tissue samples and models.

Martha Campbell-Thompson, DVM, PhD

Martha Campbell-Thompson, D.V.M., Ph.D, serves as the Pathology Core Principal Investigator at the University of Florida, where she earned doctorates in veterinary medicine and veterinary physiology. A board certified large animal veterinary surgeon, Dr. Campbell-Thompson moved into basic research after receiving her Ph.D. She has over 20 years experience in animal models of human disease with an emphasis on type 1 diabetes. She brings managerial experience to her role as primary administrator of the Pathology Core, providing histological and immunolocalization services to over 100 investigators at the University of Florida, in the United States, and overseas. In collaboration with Dr. Atkinson’s group, Dr. Campbell-Thompson has become the lead pathologist for all rodent and human type 1 diabetes studies.

Yi-Chun Chen, PhD

Dr. Yi-Chun Chen is a postdoctoral fellow working in Dr. Bruce Verchere’s laboratory at the University of British Columbia. Her research focuses on the causes and consequences of insufficient islet prohormone processing in diabetes.

Carmella Evans-Molina, MD, PhD

Dr. Carmella Evans-Molina serves as a Co-Executive Director of nPOD. She is the Eli Lilly Foundation Professor of Pediatric Diabetes at the Herman B Wells Center for Pediatric Research at the Indiana University School of Medicine in Indianapolis, IN, where she serves as the Director of the IU Center for Diabetes and Metabolic Diseases (CDMD), Director of the Pediatric Diabetes Research Program in the Herman B Wells Center, and the Director of the Indiana Diabetes Research Center Islet and Physiology Core. She is a Staff Physician at the Roudebush VA Medical Center in Indianapolis. Dr. Evans-Molina earned her MD degree from Marshall University and her PhD from the University of Virginia (UVA). She completed her residency training in Internal Medicine at the Massachusetts General Hospital and subspecialty training in Endocrinology and Metabolism at UVA.

Dr. Evans-Molina’s basic science research program is focused on defining mechanisms of altered β cell calcium signaling in type 1 and type 2 diabetes. She has a translational interest in the identification of novel biomarkers that can be used to identify those at risk of type 1 diabetes. Her research is funded by the National Institutes of Health, the US Veteran’s Administration, and the JDRF.

Dr. Evans-Molina is an investigator in the Type 1 Diabetes TrialNet Network, where she serves as Chair of the Long-Term Investigative Follow-Up in TrialNet (LIFT) Study. She is also an investigator in the NIH RADIANT and DREAM consortia.

Donna Farber, PhD

Donna L. Farber, Ph.D. is the George H Humphreys, II Professor of Surgical Sciences (in Surgery) and Professor of Microbiology and Immunology at Columbia University. The focus of Dr. Farber’s research is on anti-viral immunity and human immunology. Dr. Farber’s laboratory originally identified a specialized subset of memory T cells that take up long-term resident in tissues, such as the lung. She discovered that these lung tissue resident memory T cells mediate optimal protective immunity to respiratory virus infections. These findings led her to establish a major initiative in translational immunology to study human tissue immunity and its development from infancy through adulthood in multiple mucosal and lymphoid tissues from organ donors of all ages. Dr. Farber leads NIH/NIAID-funded Program grants on human immunity, anti-viral responses and is part of the Human Immunology Project Consortium (HIPC), and the NIH/NHLBI consortium on human lung aging. In addition to the NIH, her research is supported by the Helmsley Charitable trust and the Chan-Zuckerberg seed network for the Human Cell Atlas. She has over 150 publications, is a fellow of the AAAS, and has served on advisory committees for the NIH, American Association of Immunologists (AAI), and multiple editorial boards.

Kyle Gaulton, PhD

Kyle is an Assistant Professor in the Department of Pediatrics at UC San Diego. Kyle has a BAS in computer science from the University of Pennsylvania, a PhD in genetics and molecular biology from the University of North Carolina at Chapel Hill, and did postdoctoral training at the University of Oxford and Stanford University.

Dirk Homann, MD

Trained as a physician and immunologist/virologist in Berlin, Boston, Paris and La Jolla, Dr. Homann has a long-standing interest in autoimmune and infectious disease, in particular the generation, maintenance, modulation, pathogenic potential and protective capacity of specific T cell immunity. Dr. Homann began his work as an independent investigator at the University of Colorado, joined the faculty at Mount Sinai in 2014, and was promoted to full Professor with tenure in 2019. Active areas of preclinical investigation include T cell memory; the role of various accessory pathways in regulation of CD8+T cell responses to acute and chronic viral infections (chemokines, CD4+T cell help, SLAM family receptors, adenosine, complement system); and the concurrent therapeutic modulation of immune responses and beta cell survival in type 1 diabetes (T1D). The overarching goal of these endeavors is the development, adaptation and optimization of therapeutic strategies that effectively curtail (autoimmunity) or embellish (infectious disease) T cell responses with prophylactic and/or curative intent. Over the past decade, Dr. Homann has expanded his research program to encompass a broader context of pancreatic islet cell biology and histopathology in human T1D, and he has launched multiple collaborative efforts to better leverage complementary expert knowledge, unique technology access and more effective overall implementation of research strategies. Most recently, he has applied such strategies to delineate complex immunological signatures associated with T1D development (JDRF/TrialNet KQ1 study), and to interrogate aspects of diabetes pathogenesis specifically in the context of infection with SARS-CoV-2, the etiological agent of COVID-19

Eddie James, PhD

Dr. James received his bachelor’s degree in Chemical Engineering from the University of Colorado. He subsequently attended Washington State University, receiving his PhD in Biochemical Engineering in 2001. After completing an internship at Zymogenetics, he joined the Benaroya Research Institute as manager of the tetramer core and is currently a BRI assistant member. Dr. James is a member of the JDRF biomarker working group and co-leads the Immunology of Diabetes Society T Cell Workshop. Under the auspices of these groups, he leads biomarker development and validation projects aimed at improved disease staging of subjects who are diagnosed with type 1 diabetes. Dr. James leads several projects related to the role of epitope specific T cells in autoimmune disease.  These include studies to investigate the role of protein modifications in neo-epitope formation and studies aimed at understanding how beta cell stress contributes to the breakdown of tolerance. Dr. James participates in several collaborative projects aimed at characterizing epitope specific T cells in autoimmune patients and at risk subjects, and clinical trial participants.

Angus Jones, PhD

Angus Jones is an Associate Professor at the University of Exeter, and an Honorary Consultant Physician at the Royal Devon and Exeter Hospital. He trained in medicine in London and completed his PhD with Professor Andrew Hattersley in Exeter, studying the clincial utility of C-peptide testing in diabetes management. His research interests are in precision approaches to the management of diabetes, with a focus on practical approaches that can impact clincial practice now or in the near future. This includes approaches to improving clincial classification of diabetes, both though optimising use of classification biomarkers such as C-peptide and islet autoantibodies, and through development of prediction models to combine clincial features and biomarkers to guide diabetes classification and treatment. Additional interests include developing stratified approaches to treatment of type 2 diabetes, and, as part of his work as research lead and Deputy Director of The University of Exeter NIHR Global Health Group, approaches to effective diabetes diagnosis, monitoring and classification in low resource settings. He has previously been awarded National Institute of Health Research (NIHR) Doctoral and Clinician Scientist fellowships, and a Rising Star award from the European Association for the Study of Diabetes.

Nagesha Guthalu Kondegowda, PhD

Nagesha Guthalu Kondegowda, obtained his Ph.D., in Biotechnology from University of Mysore, India. Dr. Kondegowda is working at Arthur Riggs Diabetes and Metabolism Research Institute, City of Hope, California, in Dr. Rupangi Vasavada lab. His longstanding research focus is on finding ways to induce the growth, survival, and regeneration of functioning pancreatic beta cells in vivo. His research interests are on the role of growth factors and their signaling and molecular pathways through which they mediate effects in normal pancreatic beta cell physiology and in the pathophysiological settings of diabetes and islet transplantation. The translational goals of his research are: i) to induce human beta cell growth and function including in the setting of islet transplants; ii) to induce beta cell regeneration in vivo; iii) and to improve outcomes in animal models of type 1 and/or type 2 diabetes, either through the acute use of growth factors or downstream target molecules activated by these factors. The ultimate objective of his research is to find ways to enhance preservation and regeneration of functional beta cells in vivo, for the treatment of diabetes. His findings on osteoprotegerin and its effect on beta cell homeostasis is well received in the field of diabetes research. 

Dr. Kondegowda’s recent interest is to study the role of extracellular vesicles (EVs) derived from the circulation or tissues of patients with type 1 diabetes. Particularly, his goal is to examine how EVs at different stages of type 1 diabetes are cytotoxic to beta cell health and induce pro-inflammatory phenotype in immune cells, to identify the distinct cargo in the EVs that mediates its functional effects, and ultimately to investigate their potential as disease biomarkers.

Francisco Leon, MD, PhD

 

Francisco Leon, MD, Ph.D. is the scientific co-founder of Provention Bio, Inc. An immunologist by training, Francisco Leon has more than two decades of academic research and biopharma industry experience, with an expertise in immune tolerance. Previously, Francisco Leon was the Chief Executive Officer and Chief Medical Officer of Celimmune, LLC, aclinical stage immunotherapy company dedicated to developing transformational therapies for celiac disease and other serious immune-mediated diseases. Prior to Celimmune, Francisco Leon served as Vice President and Head of Translational Medicine/Immunology at Johnson & Johnson’s Janssen Pharmaceuticals, where he led early-stage clinical development in immunology. Francisco Leon’s professional experience is also highlighted by positions of increasing responsibility at several life sciences companies, including Chief Medical Officer of Alba Therapeutics, Director of Clinical Development, Inflammation & Respiratory at Medimmune and Director of Clinical Discovery, Immunology & Oncology at Bristol-Myers Squibb.

Prior to entering the biopharma industry, Francisco Leon served as a Postdoctoral Fellow at the National Institutes for Allergy and Infectious Diseases (NIAID) of the National Institutes of Health (NIH). In 2011, he became an Associate Professor of Medicine at Jefferson Medical College in Philadelphia, where he continues to contribute to the clinical research efforts of the Department of Gastroenterology. Francisco Leon earned his MD and Ph.D. from Autónoma University in Madrid Spain and has authored or co-authored more than 80 peer-reviewed articles, book chapters and patents.

Alice Long, PhD

Dr. Alice Long received her BS degree in Biology from Macalester College in St. Paul, MN, and earned her PhD in Immunology from Emory University in Atlanta, GA. She then pursued post-doctoral studies at the University of California at Davis studying the etiology and pathogenesis of primary biliary cirrhosis, an autoimmune disease of the liver. She next joined a Seattle-based biotechnology company, Xcyte Therapies, where she helped develop adoptive T-cell therapies for multiple diseases. In 2005, she joined Benaroya Research Institute (BRI) as a staff scientist. In 2011, she joined the faculty at BRI and is currently an Associate Member and Manager of the Human Immunophenotyping Core.

Dr. Long’s lab is a translational immunology lab focused on using human samples to understand etiology, pathogenesis, disease heterogeneity and treatment response. Specifically, her current research includes three inter-related projects: 1) causes and consequences of reduced IL-2 signaling in T1D subjects, 2) cellular definition, function and stability of CD8 exhaustion associated with beneficial response to therapy, and 3) identification of biomarkers of disease progression.

Roberto Mallone, MD, PhD

R. Mallone received his MD PhD degree from the University of Turin, Italy. After a Postdoc with Jerry Nepom at the Benaroya Institute in Seattle, he moved to Paris where he is currently Professor of Immunology at Paris Descartes University, Diabetologist at the Cochin Hospital and leads a research team at the INSERM Cochin Institute. His research focuses on autoimmune T cells and the understanding of type 1 diabetes mechanisms in order to develop T-cell-based biomarkers and therapeutics.

Major contributions to the field include the demonstration of the central role of CD8+ T cells in beta-cell autoimmunity, the development of T-cell assays to clarify disease mechanisms and therapeutic modifications, and the exploration of perinatal vaccination strategies. More recently, he described a universal state of ‘benign’ islet autoimmunity imprinted in the thymus and the first immunopeptidome of human beta cells, identifying novel granule antigens targeted by CD8+ T cells.

Maki Nakayama, MD, PhD

The primary focus of Dr. Nakayama’s laboratory is to elucidate the mechanism by which anti-islet autoimmunity causing type 1 diabetes (T1D) is initiated, from the point of view of the tri-molecular complex consisting of antigen, major histocompatibility complex (MHC), and T cell receptor (TCR) that could be a key component for the development of T1D. One of current major goals is to identify antigen specificity of T cells infiltrating pancreatic islets of T1D patients and to illustrate whether and how antigen specificity determines T cell fate.

Dr. Nakayama and her colleagues recently identified TCR clonotypes expressed by T cells in the islets of organ donors with and without T1D and demonstrated that peptides derived from preproinsulin are the target antigen for islet-infiltrating T cells.  Islets of T1D donors contain the higher frequency of T cells that respond to antigen more strongly compared to those of non-diabetic donors. The laboratory currently seeks to determine the role of preproinsulin-reactive T cells in T1D development as well as continues to explore antigen specificity for islet-infiltrating cells.  In addition, they pursue the potential of TCR sequences to be used as T cell biomarker to predict the development of T1D. 

Julia Panzer, PhD

Dr. Julia Panzer is a postdoctoral fellow at the University of Miami Miller School of Medicine. She initially trained as a chemist and pursued her Ph.D. in human biology in Germany. During her doctoral studies she helped implement the human slice platform to study islets in their native environment. Her current projects focus on alpha cell function and human islet development.

Feroz Papa, MD, PhD

Feroz Papa is a Professor of Medicine and a physician-scientist at the University of California San Francisco. Dr. Papa completed his medical and graduate school training in biochemistry and molecular biology at the University of Chicago, then did post-graduate clinical training in internal medicine and endocrinology at the University of California San Francisco.

His lab aims to understand, at the molecular, cellular and organismal levels, how protein unfolding in the endoplasmic reticulum (ER) causes human disease. Using this fundamental understanding, they are pioneering new therapeutic approaches for various human diseases caused by protein unfolding in the ER.

Alberto Pugliese, MD

Alberto Pugliese, MD, the J. Enloe and Eugenia J. Dodson Chair in Diabetes Research, is a Professor of Medicine, Microbiology and Immunology at the Miller School of Medicine, University of Miami, and is based at the Diabetes Research Institute. He has dedicated his professional life to type 1 diabetes research, contributing to the study of genetic factors, the disease pathogenesis, prediction, and clinical trials. He has investigated type 1 diabetes throughout its natural history, from its preclinical stages to onset, and then after diagnosis in the setting of transplantation. He serves as Executive Co-Director of the JDRF nPOD, and has dedicated much effort to facilitate scientific progress through team science approaches.

Estefania Quesada-Masachs, MD, PhD

I obtained my MD degree at University of Barcelona (UB) in 2008. I finished my residency in Rheumatology and in Pediatric Rheumatology at Vall d’Hebron University Hospital. At early stages of my career I got fascinated by biomedical research and hence I got involved in multiple clinical research projects and clinical trials. I also did a fellowship at Istituto Giannina Gaslini in Italy, Center of Excellence in Pediatric Rheumatology according to the European League Against Rheumatism (EULAR). In 2017 I obtained my PhD at Autonomous University of Barcelona (UAB) with a cum laude and the mention as an international doctor. My PhD thesis was focused on identifying immunological differences in relation to age and treatment in patients with Juvenile Idiopathic Arthritis.

I joined Prof. von Herrath’s lab as a postdoctoral fellow at La Jolla Institute for Immunology in 2018, where I am studying type 1 diabetes, investigating the role of different immune cells, cytokines and other signaling molecules in disease initiation and progression. I perform experiments in human pancreatic sections obtained from the Network for Pancreatic Organ Donors with Diabetes (nPOD), in human isolated islets (IIDP) and in human islet microtissues (InSphero). I also work with animal models. I am particularly interested in gaining insight in the processes occurring in autoimmune diseases that start in childhood.

Maria J. Redondo, MD, PhD

Dr. Redondo is Professor of Pediatrics at Baylor College of Medicine and a Pediatric Endocrinologist at Texas Children’s Hospital in Houston, Texas, United States.

Dr. Redondo’s research overall goal is to dissect the heterogeneity of diabetes to bring closer the goal of precision medicine. One of her NIH NIDDK funded projects aims to incorporate genetic risk scores in the predictive model for type 1 diabetes and use genetics to improve the selection of candidates for prevention trials in the Type 1 Diabetes TrialNet Study. Her Diabetes Study in Children of Diverse Ethnicity and Race (DISCOVER), also funded by NIDDK, seeks to use genetics for timely and accurate diagnosis of diabetes type in children of diverse ancestry with the ultimate goal to improve clinical outcomes. She is also part of the NIDDK-funded Rare and Atypical Diabetes Network (RADIANT), and the American Diabetes Association Precision Medicine in Diabetes Initiative.

Scott A. Soleimanpour, M.D.

Scott Soleimanpour, M.D. is an Associate Professor of Internal Medicine and Molecular and Integrative Physiology, Co-Director of the JDRF Center of Excellence at the University of Michigan, and Associate Director of the University of Michigan Caswell Diabetes Institute. Diagnosed with type 1 diabetes (T1D) in 1986, Dr. Soleimanpour is deeply invested in basic research focused on the genetic causes of beta cell failure in both T1D and type 2 diabetes (T2D). Dr. Soleimanpour attended Kent State University and the Northeast Ohio Medical University as part of a combined B.S./M.D. program. During his pre-doctoral and post-doctoral research training, Dr. Soleimanpour completed diabetes research fellowships in the Vanderbilt University/NIDDK medical scholars program, the Howard Hughes Medical Institute-National Institutes of Health (HHMI-NIH) Research Scholars program, and the William Osler Society of Fellows at the University of Pennsylvania before joining the faculty at Penn and moving to the University of Michigan in 2014. Among Dr. Soleimanpour’s key research contributions include studies focused on islet cell transplantation, the mitochondrial life cycle, and include seminal studies focused on control of pancreatic beta cell function by mitophagy.   He has received awards and honors from the American Diabetes Association, Juvenile Diabetes Research Foundation, the American Society of Clinical Investigation, the Central Society for Clinical and Translational Research, the Alpha Omega Alpha National Medical Honors Society, and The Endocrine Society. The Soleimanpour Lab has pioneered the study of mitochondrial quality control in diabetes pathophysiology, and his lab continues to focus on how defects in the key mitophagy gene Clec16a lead to beta cell dysfunction in both T1D and T2D.

Peter Thompson, PhD

Peter earned his Ph.D. in Medical Genetics at the University of British Columbia. He moved into the fields of islet biology and Type 1 Diabetes (T1D) during his postdoctoral training at the University of California San Francisco (UCSF), where his work discovered senescence as a new form of beta cell dysfunction in T1D. He was funded by the Diabetes Research Connection, the Larry L. Hillblom Foundation and the Program for Breakthrough Biomedical Research at UCSF. In 2020, he became an Assistant Professor in the Department of Physiology & Pathophysiology at the University of Manitoba and a Principal Investigator in the Children’s Hospital Research Institute of Manitoba.

John Virostko, PhD

Jack Virostko performs quantitative biomedical imaging in both preclinical and clinical studies. He has experience with MRI, nuclear imaging and optical imaging and performing both technological development and application – primarily to the fields of oncology, diabetes and metabolism.

Virostko received his bachelor’s in mechanical engineering from Georgia Institute of Technology and his masters and doctorate in biomedical engineering from Vanderbilt University. He received postdoctoral training at the University Institute of Imaging Science followed by completion of a master’s in clinical investigation.

Kate White, PhD

 

Kate White is a cell biologist, structural biologist, and pharmacologist interested in developing experimental methods for 3-dimensional visualization of single cells to characterize the cellular ultrastructure to mesoscale organization. She is also interested in helping to develop integrative whole-cell modeling infrastructure to harmonize structural and mathematical representations of the cell across the scales of biology.

Dr. White is Gabilan Assistant Professor of Chemistry at USC. She received her Ph.D. in Pharmacology in 2014 from the University of North Carolina, Chapel Hill, under the mentorship of Dr. Bryan Roth. After continuing her postdoctoral training in protein structural biology at the University of Southern California with Professor Raymond Stevens, she then took on the role of Associate Director of the Bridge Institute at USC. Now, Dr. White is the Director of the Pancreatic Beta Cell Consortium (PBCC), an interdisciplinary and collaborative team of scientists with the common goal of understanding beta-cell biology and its role in diabetes.